# OnCo record prodige-23 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/prodige-23/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "prodige-23", "NCT01804790" ;
  schema:name "PRODIGE 23"@en ;
  schema:description "PRODIGE 23 showed that six cycles of intensive chemotherapy before chemoradiation improves disease-free survival in rectal cancer and, on longer follow-up, overall survival, the second pillar of total neoadjuvant therapy."@en ;
  schema:url <https://onco.cc/trials/prodige-23/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01804790>, <https://doi.org/10.1016/S1470-2045(21)00079-6> ;
  onco:status "positive" ;
  onco:tag "radiation-wave4" ;
  onco:phase "3" ;
  schema:startDate "2012-01" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/rectal-cancer/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/unicancer/> ;
  onco:terms <https://onco.cc/terms/chemoradiation/> ;
  onco:trials <https://onco.cc/trials/stellar-rectal/>, <https://onco.cc/trials/cao-aro-aio-12/>, <https://onco.cc/trials/iwwd/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021/> .